“The emerging role of capivasertib in breast cancer”

Over 50% of breast tumors harbor alterations in one or more genes of the phosphatidylinositol 3-kinase (PI3K) pathway including PIK3CA mutations (31%), PTEN loss (34%), PTEN mutations (5%) and AKT1 mutations (3%). While PI3K and mTOR inhibitors are already approved in advanced breast cancer, AKT inh...

Full description

Bibliographic Details

Published in:	Breast
Main Authors:	Angeliki Andrikopoulou, Spyridoula Chatzinikolaou, Evangelia Panourgias, Maria Kaparelou, Michalis Liontos, Meletios-Athanasios Dimopoulos, Flora Zagouri
Format:	Article
Language:	English
Published:	Elsevier 2022-06-01
Subjects:	Capivasertib” “Breast cancer” “AKT inhibitor” “PI3K/AKT/mTOR pathway”
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977622000728